AbbVie Stock Rises After FDA Approves 3rd Headache Drug

ABBV is up 23% year-over-year

Digital Content Manager
Sep 29, 2021 at 10:02 AM
facebook twitter linkedin


The U.S. Food and Drug Administration (FDA) just approved AbbVie Inc's (NYSE:ABBV) migraine prevention treatment, marking the company's third drug in its roster for severe headaches. The once-daily oral migraine medicine, known as Qulipta is one of the drugs acquired by ABBV in its $63 billion deal to buy Allergan that happened last year. 

ABBV was last seen up 0.6% at $107.95, though pressure still looms at the 20-day moving average. The stock has ben trading in a tight channel between its $108 an $106 levels since plummeting from its four-year high of $121.53 in mid-September. The stock has been testing support at its year-to-date breakeven level, though it sports a 23% year-over-year lead. 

Sentiment among analysts remains high, and of the 13 covering ABBV, just three say "hold," compared to 10 "buy" or better ratings. Plus, the 12-month consensus price target of $127.01 is a 17.5% premium to current levels. 

Options traders have also been optimistic. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity's 10-day call/put volume ratio of 3.59 stands higher than 86% of readings from the past year. This means long calls have rarely been more popular. 

Echoing this, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.39 is higher than just 4% of readings in its annual range, implying short-term options traders have been much more call-biased than usual. 

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners